Clinical trial
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone…
NCT00057564 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00057564 |
|---|---|
| Title | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma |
| Official title | A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | A (Thalidomide + Dexamethasone), B (Placebo + Dexamethasone) |
| Enrollment | 470 |
| Start date | Feb 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Aug 1, 2013 |
| First posted | Apr 7, 2003 |
| Last update posted | Sep 11, 2015 |
| Countries | Australia, Belgium, Bulgaria, Canada, Germany, Hungary, Ireland, Israel, Italy, Poland, Russia, Spain and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: